Literature DB >> 35490440

SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.

I Backhaus1, D Hermsen2, J Timm3, F Boege2, N Lübke3, T Degode4, K Göbels4, N Dragano5.   

Abstract

OBJECTIVES: Most SARS-CoV-2 seroprevalence studies have focussed on adults and high-risk populations, and little is known about young adults. The objective of the present study was to provide evidence on the SARS-CoV-2 seroprevalence among young adults in Germany and to explore determinants associated with seropositivity in general and, specifically, with previously undetected infections. STUDY
DESIGN: This was a population-based SARS-CoV-2 seroprevalence study.
METHODS: In November 2020, a population-based study on SARS-CoV-2 seroprevalence in young adults (aged 18-30 years) was conducted in a large German city. Serum samples were obtained to analyse the SARS-CoV-2 antibody status using the Elecsys Anti-SARS-CoV-2 immunoassay. Descriptive statistics and odds ratios (ORs) of seropositivity and of previously undetected infections in relation to different determinants were calculated.
RESULTS: Among 2186 participants, SARS-CoV-2 antibodies were detected in 72 individuals, equalling a test performance-adjusted seroprevalence of 3.1% (95% confidence interval [CI]: 2.4-4.0). Based on reported COVID-19 cases to the public health authority, a moderate underascertainment rate of 1.7 was calculated. Seropositivity was higher among individuals who sought COVID-19-related information from social media (OR: 1.83, 95% CI: 1.2-3.1), and undetected COVID-19 infections were more prevalent among men and those not adhering to social distancing.
CONCLUSIONS: The results show a substantial underascertainment of SARS-CoV-2 infections among young adults and indicate that seroprevalence is likely to be much higher than the reported COVID-19 prevalence based on confirmed COVID-19 cases in Germany. Preventive efforts should consider the heterogeneity of risk profiles among the young adult population.
Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2 antibodies; Seroprevalence; Young adults

Mesh:

Substances:

Year:  2022        PMID: 35490440      PMCID: PMC8940565          DOI: 10.1016/j.puhe.2022.03.009

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   4.984


Introduction

In Germany, the new coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), first appeared in January 2020. At the beginning of the pandemic, high incidence rates were primarily reported among the elderly population; however, the age distribution of those infected with COVID-19 began to shift when numbers started to increase significantly among the younger population in late summer 2020.1, 2, 3 Since the start of the pandemic, there have been ongoing debates about COVID-19 susceptibility in young adults; however, empirical evidence remains scarce and often inconclusive.4, 5, 6 In this context, the use of seroprevalence studies, which assess the number of people in a population who test positive for a specific disease based on blood serum, can help to determine the number of infections at the population level and to identify the magnitude of undetected cases. Currently, however, most SARS-CoV-2 seroprevalence studies have focussed on the general population or on specific high-risk groups (e.g. hospital staff), , and only a few studies have considered young adults. In some studies, the sample size was too small to enable age group–specific evaluations, and in the larger studies, young adults were frequently not considered as a separate group.9, 10, 11 In studies that did evaluate young adults, only descriptive analyses were conducted; , for example, findings from Europe determined the seroprevalence for individual age groups and found that it was highest among 20- to 34-year-olds. , To the best of our knowledge, to date, more in-depth studies among young adults have not been carried out. Many previous studies were conducted during the first pandemic wave, at a time when the COVID-19 incidence was relatively low among young people. From a public health perspective, data on SARS-CoV-2 seroprevalence among young adults are of great importance for several reasons, including (1) young adults are characterised by a high number of asymptomatic cases, which may contribute to the undetected transmissions of the disease; (2) young adults are characterised by distinct determinants, including low-risk perception and high mobility; , and (3) although most young adults experience a mild disease course, there are increasing concerns of long-term adverse health effects and identifying factors linked to infection risk (both detected and undetected) can help to understand SARS-CoV-2 transmission dynamics and consequently support the development of targeted prevention measures. The present study aims to provide evidence on SARS-CoV-2 seroprevalence among young adults in Germany in November 2020 (i.e. during the second pandemic wave in Germany) and to explore determinants associated with seropositivity in general and, specifically, with previously undetected infections.

Methods

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for reporting cross-sectional studies was followed in the present study.

Study design, population and sampling

SERODUS is a population-based, cross-sectional seroepidemiological study, which was conducted in Düsseldorf (Germany) between 2 and 27 November 2020. The sampling frame consisted of all individuals aged 18–30 years who were registered in Düsseldorf in October 2020 (n = 106,449). The study sample was selected via random sampling through the population registry (Fig. 1 ). The minimum sample size was calculated to be 1600–2000 individuals, with 95% confidence limits and assuming an anticipated seroprevalence of 1–6% or lower. The anticipated seroprevalence of 1–6% was chosen based on earlier reports that suggested a SARS-CoV-2 seroprevalence of between 1% and 6% in the general adult population.17, 18, 19 To estimate even simple group differences with acceptable error intervals, the target corridor was a net sample of 2000 ± 400 individuals. Inclusion criteria were (1) permanent residence in Düsseldorf, (2) aged 18–30 years at that date when the serum sample was taken and (3) providing written informed consent. All potential participants were invited through written personal postal invitation letters (step 1) sent to their private mailboxes, including information about the study, a personal invitation number and a link to the study website. If interested in participation, an appointment could be made via the study hotline. Given the short recruitment phase of 14 days, reminder letters were sent out 5 days after the initial invitation (step 2).
Fig. 1

Flow diagram of participant recruitment, enrolment, and study completion.

Flow diagram of participant recruitment, enrolment, and study completion.

Informed consent

Participants provided written and informed consent.

Measures

The primary study outcome was SARS-CoV-2 seroprevalence, and the secondary outcome was determinants associated with seropositivity. After providing written and informed consent, study participants completed a self-administered questionnaire, and a blood sample was taken. Established survey instruments were used to obtain information on participants' sociodemographics (e.g. age and educational level), COVID-19-related symptoms (e.g. fever), chronic conditions (e.g. diabetes), exposure (e.g. participation in festivities) and behaviour-related factors (e.g. adherence to COVID-19 public health measures). Questions relating to sociodemographic characteristics were taken from the demographic standards defined by the German federal statistics office. Questions concerning adherence to and support of COVID-19-related public health measures were taken from a COVID-19 questionnaire provided by the Robert Koch Institute, Germany's central public health authority. General adherence to public health measures was assessed by asking respondents, “To what extent do you adhere to the coronavirus containment measures, which came into effect on March 18, 2020?” Specific public health measures investigated included social distancing (in private and public settings) and wearing a face mask in public. The type and frequency of the source used to retrieve COVID-19-related information were investigated by asking respondents, “How often do you use social media for COVID-19-related information?” All study material was provided in German, English, Turkish and Arabic languages.

Laboratory analysis and assays

Serum samples were tested for antibodies (including IgG, IgA and IgM) against the nucleocapsid antigen of SARS-CoV-2 (N) using the Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, Mannheim, Germany). The assay was performed on a Cobas e801 analyser (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The results showing a cut-off index (COI) of <1.0 were classified as negative, and a COI ≥1.0 was deemed positive for anti-SARS-CoV-2 antibodies (hereinafter referred to as seropositive). According to internal study data of Roche Diagnostics, the overall clinical specificity of the Elecsys Anti-SARS-CoV-2 immunoassay was 99.8% containing no cross-reactivity to the common cold coronaviruses, and additionally, a clinical sensitivity of 99.5% was calculated ≥14 days post polymerase chain reaction (PCR) confirmation. Serum samples with positive results were subject to SARS-CoV-2 neutralisation assay to detect SARS-CoV-2 neutralising antibodies with a titre of ≥1:10 being considered positive.

Data analysis

Data analysis followed a three-step approach. First, descriptive statistics, including the calculation of frequencies and percentages, were performed to describe the sample and the seroprevalence among young adults. Second, the underascertainment rate of SARS-CoV-2 infections was calculated. This was based on the ratio of two population proportions: the proportion of SARS-CoV-2 infections calculated from our study and the cumulative incidence of non-fatal PCR-positive cases in the young adult population of Düsseldorf. These estimates were adjusted for test sensitivity (99.5%) and specificity (99.8%) of the Roche Cobas Elecsys Anti-SARS-CoV-2 test. Third, to investigate the association between seropositivity and possible risk factors, a series of logistic regressions to calculate odds ratios (ORs) were performed. Specifically, the OR for seropositivity was estimated separately for each main exposure of interest (e.g. adherence to public health measures, travelling outside the European Union [EU] etc.; Model 1). In Model 2, each estimate was adjusted for age and sex (the estimate for age is adjusted only for sex, and the estimate for sex is adjusted only for age). Analyses were performed using Stata version 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). All statistical models fit the data well according to the Hosmer–Lemeshow goodness-of-fit test (see supplementary material Table S1).

Results

A total of 2189 individuals attended the study centre (Fig. 1). Three observations were excluded because the individuals could not be tested (e.g. syncope). This yielded an analytic sample of 2186 individuals (24% of those invited) with complete records (i.e. informed consent, questionnaire and laboratory results; Fig. 1).

Sample characteristics

Table 1 shows the sociodemographic characteristics, and Table 2 shows the health- and behaviour-related characteristics of the study participants. Of 2186 participants, 60.7% were female, 37.2% were aged 20–25 years, and 16.9% had a migration background (Table 1). Most participants rated their health as good (81%) and chronic conditions were rare, with only 9.2% of participants reporting having one or more chronic conditions (Table 2).
Table 1

Sociodemographic characteristics of study participants (n = 2186).

CharacteristicsParticipants, n (%)
Sex
 Female1327 (60.7)
 Male857 (39.2)
 Missing2 (0.1)
Age group
 <20 years139 (6.4)
 20–25 years813 (37.2)
 26–30 years1218 (55.7)
 Missing16 (0.7)
Household size
 1 person575 (26.3)
 2 persons1027 (47.0)
 ≥3 persons567 (25.9)
 Missing17 (0.8)
Educational levela
 Lower and middle171 (7.8)
 Higher1921 (87.9)
 Still a student or other type of education81 (3.7)
 Missing13 (0.6)
Employment status
 Not workingb110 (5.0)
 Part-time and short-term (reduced working hours)164 (7.5)
 Full time1180 (54.0)
 Student703 (32.2)
 Missing29 (1.3)
Migration background
 Yes370 (16.9)
 No1803 (82.5)
 Missing13 (0.6)

Participants' education level was assessed according to the 2011 version of the International Standard Classification of Education (ISCED) and grouped into low/middle education (e.g. primary education) and higher education.

This also includes pensioners and parents on maternity leave.

Table 2

Health-related characteristics and social determinants of study participants (n = 2186).

CharacteristicsParticipants, n (%)
Self-reported health
 Very good/excellent1771 (81.0)
 Fair/bad385 (17.6)
 Missing30 (1.4)
Chronic condition
 No1975 (90.3)
 Yes201 (9.2)
 Missing10 (0.5)
PCR test since February 2020
 Yes784 (35.9)
 No, no test needed1126 (51.5)
 No, but I thought about getting tested194 (8.9)
 No, I asked for a test but did not get one72 (3.3)
 Missing10 (0.5)
Self-reported COVID-19
 Yes46 (2.1)
 No728 (33.3)
 I do not know10 (0.4)
Symptoms since February 1a
 Fever ≥38 °C225 (10.3)
 Cough648 (29.8)
 Pneumonia7 (0.3)
 Dyspnoea/shortness of breath121 (5.6)
 Pain when breathing112 (5.2)
 Congested/running nose848 (39.0)
 Sore throat854 (39.1)
 Loss of smell or taste100 (4.6)
 No symptoms511 (23.5)
Contact to a confirmed COVID-19 case
 No1711 (78.3)
 Yes, with a distance ≥1.5 m179 (8.2)
 Yes, with a distance <1.5 m285 (13.0)
 Missing11 (0.5)
Other exposuresa
 Working with patients262 (12.0)
 Working with customers340 (15.6)
 Participated in an event with ≥50 persons850 (39.1)
 Travelled outside the EU246 (11.3)
 Travelled within the EU1068 (49.0)
General adherence to public health measuresb
 Adheres completely to public health measures1243 (56.9)
 Adheres partly to public health measures919 (42.0)
 Adheres little to public health measures9 (0.4)
 Does not adhere to public health measures at all0 (0.0)
 Missing15 (0.7)
COVID-19 information resource: social media
 Rarely/never1488 (68.1)
 Often/always686 (31.4)
 Missing12 (0.5)
Trust in COVID-19 information from social media influencer
 Trust277 (12.7)
 No trust1891 (86.5)
 Missing18 (0.8)
Supporting social distancing in private (contact restriction)
 Yes1968 (90.0)
 No204 (9.4)
 Missing14 (0.6)
Supporting social distancing in public (at least 1.5 m distance)
 Yes2126 (97.3)
 No488 (2.2)
 Missing12 (0.5)
Supporting wearing a face mask in public spaces
 Yes2165 (99.0)
 No13 (0.6)
 Missing8 (0.4)
Supporting the travel restriction
 Yes1991 (91.1)
 No169 (7.7)
 Missing26 (1.2)

PCR, polymerase chain reaction.

Multiple replies were possible.

In the following analyses, the categories "partly" and "little" were categorised as "partly, adherence to public health measures was assessed by asking respondents.

Sociodemographic characteristics of study participants (n = 2186). Participants' education level was assessed according to the 2011 version of the International Standard Classification of Education (ISCED) and grouped into low/middle education (e.g. primary education) and higher education. This also includes pensioners and parents on maternity leave. Health-related characteristics and social determinants of study participants (n = 2186). PCR, polymerase chain reaction. Multiple replies were possible. In the following analyses, the categories "partly" and "little" were categorised as "partly, adherence to public health measures was assessed by asking respondents.

Seroprevalence

Of 2186 young adults who participated in the present study, a total of 72 individuals were seropositive, representing a crude prevalence rate of 3.3% (95% confidence interval [CI]: 2.6–4.1) and a test-adjusted prevalence of 3.1% (95% CI: 2.4–4.0; Table 3 ). The cumulative incidence of reported cases in the population aged 18–30 years was 1.8% (as of November 2020). Based on the estimated test-adjusted seroprevalence of 3.1% and the cumulative incidence of 1.8%, it is estimated that approximately 1.7-fold more infections occurred than were ascertained by confirmed case counts. Only 31 (43.1%) of individuals with antibodies had tested positive for COVID-19 by PCR before the present study. Consequently, the within-study ‘true’ rate of unreported COVID-19 cases in this population is 2.3. Among the 72 seropositive individuals, neutralising antibodies were detected in 66 individuals (91.7%; Table 3).
Table 3

Comparison of different prevalence measures of SARS-CoV-2 antibodies (n = 2186).

Prevalence measureSARS-CoV-2 seroprevalence (unadjusted, n = 72), % (95% CI)]SARS-CoV-2 seroprevalence (adjusteda, n = 72), % (95% CI)Participants with neutralising antibodies titresb (n = 66), % (95% CI)
Overall seroprevalence3.3 (2.6–4.1)3.1 (2.4–4.0)3.0 (2.4–3.8)
Percentage of those who are seropositive and had a positive PCR before study2.1 (1.6–2.8)1.9 (1.4–2.6)N/A
Percentage of those with neutralising antibody titres and a positive PCR before study45.5 (34.0–57.4)45.0 (34.1–57.6)N/A

CI, confidence interval; N/A, not applicable.

Adjusted for Roche Cobas Elecsys Anti-SARS-CoV-2 test sensitivity and specificity.

Only in case of a positive Roche Cobas Elecsys Anti-SARS-CoV-2 test (n = 66) neutralising antibody titre assay was performed.

Comparison of different prevalence measures of SARS-CoV-2 antibodies (n = 2186). CI, confidence interval; N/A, not applicable. Adjusted for Roche Cobas Elecsys Anti-SARS-CoV-2 test sensitivity and specificity. Only in case of a positive Roche Cobas Elecsys Anti-SARS-CoV-2 test (n = 66) neutralising antibody titre assay was performed.

Determinants of a SARS-CoV-2 infection

Table 4 and Table S2 provide a detailed presentation of seroprevalence by sociodemographic and health-related characteristics. The proportion of men with positive SARS-CoV-2 antibodies (3.8%) was slightly higher than the proportion of women (2.7%). The odds of being seropositive was significantly higher among those with self-reported COVID-19 symptoms, such as loss of smell (OR: 55.6, 95% CI: 30.7–99.0), loss of taste (OR: 40.8, 95% CI: 23.0–75.5), fever ≥38 °C (OR: 5.06, 95% CI: 3.0–8.6), dyspnoea and shortness of breath (OR: 4.15, 95% CI: 2.1–7.6; Table S2). The odds of being seropositive were also almost two times higher for those who seek COVID-19-related information from social media (Table S2; OR: 1.83, 95% CI: 1.2–3.1). An increasing trend was seen in individuals who trust information from social media influencers (OR: 1.78, 95% CI: 0.9–3.3) and who do not support social distancing (Table S2; OR: 1.81, 95% CI: 0.9–3.7). Unexpectedly, we did not find evidence for a significant association between low self-reported general adherence to COVID-19 public health measures and seroprevalence (Table S2; OR: 0.91, 95% CI: 0.5–1.5) or for participants who had travelled both within (Table S2; OR: 0.98, 95% CI: 0.6–1.6) and outside (Table S2; OR: 0.72, 95% CI: 0.3–1.8) the EU. Interestingly, no significant associations were found for those aged 20–25 years (OR: 1.27; 95% CI: 0.4–3.9), individuals with a secondary school education (OR: 1.15; 95% CI: 0.4–2.9) and those who worked with patients (OR: 1.12, 95% CI: 0.5–2.4) and customers (OR: 1.36, 95% CI: 0.78–2.38).
Table 4

SARS-CoV-2 seroprevalence in young adults and determinants of infection (n = 2186).

CharacteristicDistribution among seropositive participants
OR for being seropositive unadjusted
OR for being seropositive adjusted for age and sexa
Distribution among seropositive participants, but without prior self-reported SARS-CoV-2 infection (positive by PCR)b
%c [95% CI]; nOR [95% CI]OR [95% CI]%c [95% CI]; n
Sex
 Male3.8% [2.7–5.3]; 34RefdRef2.6% [1.7–3.9]; 23
 Female2.7% [1.9–3.7]; 380.70 [0.42–1.15]0.70 [0.42–1.16]1.3% [0.7–2.0]; 18
 Missing (n)00
Age group
 <20 years2.7% [0.9–7.0]; 4RefRef2.0% [0.6–6.2]; 3
 20–25 years3.4% [2.3–4.9]; 291.27 [0.4–3.9]1.30 [0.6–2.0]2.2% [1.13–3.5]; 19
 26–30 years2.9% [2.0–4.0]; 371.07 [0.4–3.3]0.94 [0.4–2.0]1.3% [0.8–2.2]; 18
 Missing (n)21
Household size
 1 person3.1% [1.9–4.9]; 19RefRef1.6% [0.8–3.1]; 10
 2 persons3.2% [2.3–4.6]; 351.03 [0.6–1.9]1.06 [0.6–2.0]1.8% [1.1–2.9]; 20
 ≥3 persons2.8% [1.7–4.6]; 170.90 [0.4–1.8]0.94 [0.6–2.0]1.6% [0.8–3.1]; 10
 Missing (n)11
Educational level
 Lower/middle2.7% [1.1–6.5]; 5RefRef1.0% [0.1–4.2]; 2
 Higher3.2% [2.4–4.1]; 641.15 [0.4–2.9]1.52 [0.50–4.63]1.9% [1.2–2.5]; 37
 Still a student/other degree2.3% [0.5–8.4]; 20.83 [0.1–5.0]1.10 [0.17–7.18]2.3% [0.5–8.4]; 2
 Missing (n)10
Employment status
 Full time3.1% [2.2–4.3]; 39RefRef1.7% [1.1–2.7]; 22
 Not working5.3% [2.3–11.3]; 61.73 [0.7–4.3]1.88 [0.7–4.7]2.7% [0.8–8.1]; 3
 Part-time or reduced working hours4.1% [1.9–8.4]; 71.32 [0.6–3.1]1.43 [0.6–3.4]12
 Student2.2% [1.3–3.7]; 170.71 [0.4–1.32]0.71 [0.4–1.3]1.7% [0.9–3.1]; 13
 Missing34.4% [2.3–21.7]; 1
Migration background
 No3.2% [2.4–4.1]; 60RefRef1.6% [1.1–4.1]; 32
 Yes2.5% [1.3–4.7]; 100.79 [0.4–1.62]0.81 [0.4–1.65]1.8% [0.7–3.8]; 7
 Missing (n)22

CI, confidence interval; OR, odds ratio.

The estimates for household size, education, employment status and migration background are adjusted for age and sex, the estimate for age is adjusted only for sex and the estimate for sex is adjusted for age only.

For the analysis of subjects with antibodies but without self-reported SARS-CoV-2 infection, subjects with positive PCR test (n = 46) or unknown PCR result (n = 10) were excluded, resulting in a sample size of 2130 participants.

This is the test-adjusted seroprevalence; row-percentages.

Ref = reference category.

SARS-CoV-2 seroprevalence in young adults and determinants of infection (n = 2186). CI, confidence interval; OR, odds ratio. The estimates for household size, education, employment status and migration background are adjusted for age and sex, the estimate for age is adjusted only for sex and the estimate for sex is adjusted for age only. For the analysis of subjects with antibodies but without self-reported SARS-CoV-2 infection, subjects with positive PCR test (n = 46) or unknown PCR result (n = 10) were excluded, resulting in a sample size of 2130 participants. This is the test-adjusted seroprevalence; row-percentages. Ref = reference category.

Determinants of an undetected SARS-CoV-2 infection

Table 4 and Table S2 also show a subgroup analysis of participants who were seropositive but did not report a prior SARS-CoV-2 infection (right column). Because of the small sample size, ORs were not calculated, and the interpretation is based exclusively on the 95% CIs. The analysis showed that undetected infections are about twice as likely in men (2.6%, 95% CI: 1.7–3.99) than in women (1.3%, 95% CI: 0.7–2.0). The seroprevalence estimate was also considerably higher among individuals who did not adhere to social distancing (2.9%, 95% CI: 1.2–6.3) compared with individuals who adhered to social distancing (1.6%, 95% CI: 1.1–2.3) and among those who seek COVID-19-related information from social media (2.5%, 95% CI: 1.6–4.3) compared with those who did not seek COVID-19-related information from social media (1.3%, 95% CI: 0.8–2.1). The seroprevalence estimate was also higher in individuals who had considered SARS-CoV-2 testing in the past but ultimately did not go ahead with testing. Specifically, while 1.7% of total participants had an undetected infection, 5.0% (95% CI: 2.6–9.1) of those who had considered being tested and 5.4% (95% CI: 2.0–13.3) of those who had not received a test despite requesting one were seropositive. Higher prevalence estimates were also found for individuals who attended an event with >50 people (2.4%, 95% CI: 1.6–3.8) and who travelled outside the EU (2.3%, 95% CI: 0.9–5.1).

Discussion

In the present study, a test-adjusted SARS-CoV-2 seroprevalence of 3.1% and an underascertainment factor of 1.7 were found among young adults in Germany. Factors significantly associated with SARS-CoV-2 seroprevalence included self-reported symptoms (e.g. loss of smell) and seeking COVID-19-related information from social media. Factors significantly associated with an undetected SARS-CoV-2 infection were being male, not adhering to social distancing and seeking COVID-19-related information from social media. Compared with estimates from previous national and international studies, the reported seroprevalence and underascertainment rate in the present study are lower than in the general adult population. , For example, a study from the United States determined a test-adjusted seroprevalence as high as 23% in some counties, and in Germany, Neuhauser et al. reported an underascertainment factor between 2 and 6. There are at least two possibilities that might explain the observed differences. First, most studies focussed on different age groups and specific population groups, such as healthcare personnel. , , Furthermore, younger people often experience an asymptomatic or mild SARS-CoV-2 infection, which is associated with lower serum titres. Consequently, it is possible that younger individuals have titres that fall below the threshold of serological assays, and therefore, previous infection may be less frequently detected. Second, the majority of studies were conducted at different times of the pandemic and often in hotspot areas; , , , it should be noted that the timing of the study is crucial, as seroprevalence rates may vary between different pandemic phases. Specifically, many previous seroprevalence studies were performed during the first pandemic wave in spring 2020. In Germany, during this time, significantly fewer PCR tests were performed than during the second wave (starting in November 2020), and therefore, it is likely that at the beginning of the pandemic, a much higher rate of COVID-19 cases remained undetected. Furthermore, it is important to note that to correct the seroprevalence for test sensitivity and specificity, this study applied a conservative approach by using very high sensitivity and specificity values; thus, the corrected seroprevalence is lower than the uncorrected seroprevalence. However, if sensitivity and specificity were below the manufacturer's specification, seroprevalence would be higher and the underreporting rate more distinct. In addition, it has been suggested that antibody titres decline over time. We cannot exclude the possibility that some antibody responses no longer existed by the time of the survey, which would consequently underestimate the seroprevalence. Potential determinants for seropositivity and undetected infection included self-reported symptoms and seeking COVID-19-related information from social media. The findings regarding self-reported symptoms are in line with previous reports, which show that a loss of smell and taste, as well as a fever ≥38 °C were the most strongly associated factors with SARS-CoV-2 seropositivity. , , Martínez et al., for instance, found that fever was among the most frequently described symptoms by seropositive individuals. The results regarding social media use are novel. Currently, most studies investigating social media use in times of COVID-19 focussed on preventive behaviour in general , but have not associated it with the actual SARS-CoV-2 seropositivity. Nonetheless, the results are somewhat contradictory to the findings of the present study. For example, Mahmood et al. found that social media use predicts self-efficacy and perceived threat of COVID-19, which, in turn, predicts preventive behaviour. However, in the present study, participants who sought COVID-19-related information from social media were found to be significantly more likely to be seropositive, and undetected cases in this group were almost twice as likely. It is possible that seropositive individuals in the present study viewed content that downplayed the COVID-19 infection risk, which may have led to lower adherence levels to public health measures. However, this remains speculative, as these interrelations could not be detected in the present study. Furthermore, it is important to note that these results may vary over time, might be wave sensitive (i.e. severity of this specific pandemic wave) and depend on information available and consequent knowledge about COVID-19. Nevertheless, social media platforms can play a critical role in the spread of information, particularly in times of crisis, and might impact adherence to public health recommendations. , Furthermore, given that social media platforms are often the main vehicle for communication among young adults, understanding the dynamics between content consumption and social behaviour may help design more effective communication strategies. No statistically significant results were found for the association between general adherence to COVID-19 public health measures and seropositivity. However, there was a tendency for seropositivity among individuals who reported that they were in support of social distancing. This may seem surprising at first but could be explained by the fact that adherence to prevention measures was retrospectively assessed. Therefore, information, recall bias and social desirability bias cannot be ruled out. Nonetheless, given that social distancing effectively reduces the risk of transmission and that young adults, despite their often mild disease course, can still spread the virus, they represent a subgroup of the population requiring additional attention from public health campaigns. The findings suggest that large-scale COVID-19 testing can help to detect more COVID-19 cases. The expansion and continuous development of testing are recommended to secure the containment of the pandemic. Furthermore, vaccination is also essential in younger age groups, especially as recent cross-sectional data from adolescents and young adults found evidence of new or persisting COVID-19 symptoms, such as fatigue, insomnia, headache, concentration difficulties, exercise intolerance and chest pain, 1-month postdiagnosis. , Vaccinating young adults may, therefore, help prevent the long-term health effects of COVID-19. Furthermore, recent evidence also suggests that vaccination can help reduce the transmission of the disease. Given the high mobility of young adults, increasing immunisation in this population group can help prevent transmission, thereby also protecting vulnerable groups, such as the elderly. The present study has some limitations that must be noted. First, we aimed to explore the association between specific (social) determinants and seropositivity, but the subgroups were relatively small, which unfortunately precluded detailed and robust statistical analysis. Second, the response rate of 24% was lower than that of other seroprevalence studies , but higher than an epidemiological study conducted in Germany (i.e. NAKO). Nonetheless, the response rates of the other seroprevalence studies are only comparable to a limited extent because different groups were investigated and many studies focussed on hotspot areas. The recruitment period of the present study was short (14 days), resulting in a limited number of individuals being available to participate (i.e. recruitment could not be fully completed in every format [e.g. telephone recruitment attempts]); however, it did enable calculation of SARS-CoV-2 seroprevalence at a specific point in time. Third, it is impossible to gauge whether study participants were subject to systematic bias because contact could not be established with some invitees. A comparison with the age and gender structure of the population reveals that the net sample is well represented in terms of age, but not gender. Similar to other seroprevalence studies, men were underrepresented. , However, because men often have a higher seroprevalence and more undetected infections, it is possible that the overall seroprevalence is underestimated in the present study. Finally, sampling bias may have also occurred. Specifically, the prevalence of COVID-19 infection was higher in this study than the officially reported cumulative prevalence. While the official reported cumulative prevalence among young adults was 1.8%, in the present study, 2.1% of participants reported a prior COVID-19 infection. It is likely that individuals with a prior infection were more sensitised and had an increased interest in participating. In conclusion, the findings of this study suggest that the SARS-CoV-2 seroprevalence is likely to be much higher than the reported prevalence rates based on confirmed COVID-19 cases. The results further suggest that social media play an important role in young adults’ risk perception. Given the limited amount of seroepidemiological data for young adults, a follow-up study to improve the understanding of SARS-CoV-2 seroprevalence and to better identify determinants of a SARS-CoV-2 infection is needed.

Author statements

Acknowledgements

The authors wish to thank the study participants for their contribution to the research. They also wish to thank the personnel, and past staff, at the Mitsubishi Electric Hall and the MedLog24 team.

Ethical approval

The study was approved by the institutional ethics committees of the Medical Faculty of the Heinrich Heine University (reference number: IT-TEMP-2020-1042) and was conducted in line with the Declaration of Helsinki. Study participation was voluntary and could be withdrawn at any time; refusal to participate had no consequences. All participants provided informed written consent.

Funding

This work was supported by the Ministry of Labor, Health and Social Affairs of North Rhine-Westphalia. Methodological support for this study was provided by MethodCov "Method Network to Support Covid-19 Research Projects in Measuring Social and Contextual Factors" – funded by the as part of the National Network University Medicine initiative. The funder did not have a role in the design, collection, analysis, interpretation of data and/or writing of this manuscript.

Competing interests

None declared.

Availability of data and material

The data sets used and/or analysed during the present study can be made available on reasonable request and following the approval of data protection officer of the Heinrich Heine University.
  36 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

2.  Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

Authors:  Fiona P Havers; Carrie Reed; Travis Lim; Joel M Montgomery; John D Klena; Aron J Hall; Alicia M Fry; Deborah L Cannon; Cheng-Feng Chiang; Aridth Gibbons; Inna Krapiunaya; Maria Morales-Betoulle; Katherine Roguski; Mohammad Ata Ur Rasheed; Brandi Freeman; Sandra Lester; Lisa Mills; Darin S Carroll; S Michele Owen; Jeffrey A Johnson; Vera Semenova; Carina Blackmore; Debra Blog; Shua J Chai; Angela Dunn; Julie Hand; Seema Jain; Scott Lindquist; Ruth Lynfield; Scott Pritchard; Theresa Sokol; Lynn Sosa; George Turabelidze; Sharon M Watkins; John Wiesman; Randall W Williams; Stephanie Yendell; Jarad Schiffer; Natalie J Thornburg
Journal:  JAMA Intern Med       Date:  2020-07-21       Impact factor: 21.873

3.  [The baseline assessment of the German National Cohort (NAKO Gesundheitsstudie): participation in the examination modules, quality assurance, and the use of secondary data].

Authors:  Sabine Schipf; Gina Schöne; Börge Schmidt; Kathrin Günther; Gunthard Stübs; Karin H Greiser; Fabian Bamberg; Claudia Meinke-Franze; Heiko Becher; Klaus Berger; Hermann Brenner; Stefanie Castell; Antje Damms-Machado; Beate Fischer; Claus-Werner Franzke; Julia Fricke; Sylvia Gastell; Matthias Günther; Wolfgang Hoffmann; Bernd Holleczek; Lina Jaeschke; Annika Jagodzinski; Karl-Heinz Jöckel; Rudolf Kaaks; Hans-Ulrich Kauczor; Yvonne Kemmling; Alexander Kluttig; Lilian Krist; Bärbel Kurth; Oliver Kuß; Nicole Legath; Michael Leitzmann; Wolfgang Lieb; Jakob Linseisen; Markus Löffler; Karin B Michels; Rafael Mikolajczyk; Iris Pigeot; Ulrich Mueller; Annette Peters; Stefan Rach; Tamara Schikowski; Matthias B Schulze; Christoph Stallmann; Andreas Stang; Enno Swart; Sabine Waniek; Kerstin Wirkner; Henry Völzke; Tobias Pischon; Wolfgang Ahrens
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-03       Impact factor: 1.513

4.  SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.

Authors:  Ann-Sofie Rudberg; Sebastian Havervall; Anna Månberg; August Jernbom Falk; Katherina Aguilera; Henry Ng; Lena Gabrielsson; Ann-Christin Salomonsson; Leo Hanke; Ben Murrell; Gerald McInerney; Jennie Olofsson; Eni Andersson; Cecilia Hellström; Shaghayegh Bayati; Sofia Bergström; Elisa Pin; Ronald Sjöberg; Hanna Tegel; My Hedhammar; Mia Phillipson; Peter Nilsson; Sophia Hober; Charlotte Thålin
Journal:  Nat Commun       Date:  2020-10-08       Impact factor: 14.919

5.  COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020.

Authors:  Eva Leidman; Lindsey M Duca; John D Omura; Krista Proia; James W Stephens; Erin K Sauber-Schatz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-01-22       Impact factor: 17.586

6.  The kids are not alright: A preliminary report of Post-COVID syndrome in university students.

Authors:  Julie Walsh-Messinger; Hannah Manis; Alison Vrabec; Jenna Sizemore Bs; Karyn Bishof; Marcella Debidda; Dolores Malaspina; Noah Greenspan
Journal:  J Am Coll Health       Date:  2021-07-09

7.  Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany.

Authors:  Hendrik Streeck; Bianca Schulte; Beate M Kümmerer; Enrico Richter; Tobias Höller; Christine Fuhrmann; Eva Bartok; Ramona Dolscheid-Pommerich; Moritz Berger; Lukas Wessendorf; Monika Eschbach-Bludau; Angelika Kellings; Astrid Schwaiger; Martin Coenen; Per Hoffmann; Birgit Stoffel-Wagner; Markus M Nöthen; Anna M Eis-Hübinger; Martin Exner; Ricarda Maria Schmithausen; Matthias Schmid; Gunther Hartmann
Journal:  Nat Commun       Date:  2020-11-17       Impact factor: 14.919

8.  Changing Age Distribution of the COVID-19 Pandemic - United States, May-August 2020.

Authors:  Tegan K Boehmer; Jourdan DeVies; Elise Caruso; Katharina L van Santen; Shichao Tang; Carla L Black; Kathleen P Hartnett; Aaron Kite-Powell; Stephanie Dietz; Matthew Lozier; Adi V Gundlapalli
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-10-02       Impact factor: 17.586

9.  Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges.

Authors:  Barbara Rumain; Moshe Schneiderman; Allan Geliebter
Journal:  PLoS One       Date:  2021-03-10       Impact factor: 3.240

10.  SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults.

Authors:  Sophia Björkander; Likun Du; Fanglei Zuo; Sandra Ekström; Yating Wang; Hui Wan; Natalia Sherina; Lisanne Schoutens; Juni Andréll; Niklas Andersson; Antonios Georgelis; Anna Bergström; Harold Marcotte; Inger Kull; Lennart Hammarström; Erik Melén; Qiang Pan-Hammarström
Journal:  J Allergy Clin Immunol       Date:  2021-10-23       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.